Evidence map›Paper›PMID 39343508›Full record

ArticleJournal for immunotherapy of cancer2024

Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade.

Nicola Principe, Amber-Lee Phung, Kofi L P Stevens, Omar Elaskalani, Ben Wylie, Caitlin M Tilsed, Fezaan Sheikh, M Lizeth Orozco Morales, Joel Kidman, Elly Marcq and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nicola PrincipeInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.ORCID http://orcid.org/0000-0001-6458-2482
Amber-Lee PhungInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.
Kofi L P StevensInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.
Omar ElaskalaniTelethon Kids Institute, Nedlands, Western Australia, Australia.
Ben WylieTelethon Kids Institute, Nedlands, Western Australia, Australia.
Caitlin M TilsedPerelman School of Medicine, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Fezaan SheikhInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.
M Lizeth Orozco MoralesInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.
Joel KidmanInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.
Elly MarcqCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerpen, Belgium.
Scott A FisherInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.
Anna K NowakInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.
Alison M McDonnellTelethon Kids Institute, Nedlands, Western Australia, Australia.
W Joost LesterhuisTelethon Kids Institute, Nedlands, Western Australia, Australia.
Jonathan CheeInstitute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia jonathan.chee@uwa.edu.au.ORCID http://orcid.org/0000-0002-7986-2708

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein/ligand 1 (PD-1/PD-L1) are approved for treatment of multiple cancer types. Chemotherapy is often administered with immune checkpoint blockade (ICB) therapies that target CTLA-4 and/or PD-(L)1. ICB targeting other immune checkpoints such as lymphocyte activating gene-3 (LAG-3) has the potential to improve antitumor responses when combined with chemotherapy. Response to anti-PD-1 ICB is dependent on progenitor exhausted CD8

methodsHere we investigated whether sequential chemotherapy altered T

resultsTwo doses of two different anti-metabolite chemotherapies increased tumor infiltrating CD4

conclusionsChanges in immune checkpoint expression on TILs during chemotherapy administration informs selection of ICB therapies to combine with.

Indexed as

Antigens, CDImmune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingAnimalsAntineoplastic Combined Chemotherapy ProtocolsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMiceAntigens, CDImmune Checkpoint InhibitorsLag3 protein, humanLag3 protein, mouseLymphocyte Activation Gene 3 ProteinChemotherapyCombination therapyImmune checkpoint inhibitorsT-lymphocytes

Identifiers

PMID39343508
PMCPMC11440230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.